Kuehn Law, PLLC is investigating whether Vistagen Therapeutics' officers and directors breached their duties by misrepresenting risks in their Social Anxiety Disorder clinical trials. The lawsuit claims insiders failed to disclose high placebo responses and variability in Phase 2 trials but still promoted Phase 3 trial success. Shareholders who bought stock before April 1, 2024, are urged to contact the law firm to protect their rights. This case highlights potential governance issues affecting investor confidence in Vistagen Therapeutics.
The global solar backsheet market, valued at $3.84 billion in 2025, is projected to grow to $6.91 billion by 2035 at a CAGR of 6.74%. Growth is fueled by increasing solar PV installations worldwide, investments in renewable energy infrastructure, and...
The global graphene chip market, valued at $4.41 billion in 2025, is projected to grow to $19.78 billion by 2035 with a CAGR of 16.2%. This growth is fueled by rising demand for advanced nanoelectronics, AI computing, and faster communication technol...
The global propionic acid market, valued at $1.22 billion in 2025, is projected to grow to $1.74 billion by 2035 at a CAGR of 3.63%. Growth is fueled by rising demand in food preservation, animal feed additives, pharmaceuticals, and agrochemicals. Su...
The global brain implants market, valued at $7.10 billion in 2025, is projected to grow at a CAGR of 9.99% to reach $18.39 billion by 2035. Growth is fueled by advances in neurotechnology, including deep brain stimulation and brain-computer interface...
Pan American Silver (PAAS) is rated a buy due to rising silver prices, strong Q1 earnings, and a low forward P/E near 10. The company dramatically reduced its all-in sustaining costs (AISC) to $6.63/oz in Q1 2026 from $13.88/oz a year earlier, driven...
